Literature DB >> 18443386

5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.

Violetta Sulzyc-Bielicka1, Agnieszka Bińczak-Kuleta, Wiesława Pioch, Józef Kładny, Katarzyna Gziut, Dariusz Bielicki, Andrzej Ciechanowicz.   

Abstract

DPYD gene encodes dihydropyrimidine dehydrogenase which is the initial and rate-limiting enzyme in the metabolism of 5-fluorouracil (5-FU). The aim of our study was PCR-RFLP based-genetic testing for the most common 5-FU toxicity-attributable IVS14 + 1G > A DPYD mutation (DPYD(*)2A) in 252 Polish colorectal cancer (CRC) patients treated with this adjuvant chemotherapeutic regimen after surgery. The DPYD(*)2A allele was identified only in one patient: a male who was one of 4 CRC patients suffering from grades 3-4 myelotoxicity upon 5-FU chemotherapy. We conclude that IVS14 + 1G > A DPYD (DPYD(*)2A) variant occurs in the Polish population and is responsible for a significant proportion of life-threatening toxicity of 5-FU.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443386

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  5 in total

1.  Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.

Authors:  Timur Cerić; Nermina Obralić; Lejla Kapur-Pojskić; Drazenka Macić; Semir Beslija; Anes Pasić; Sejla Cerić
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

Review 2.  DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-08-12

3.  Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer.

Authors:  Juanzi Zeng; Heming Wu; Qingyan Huang; Jiaquan Li; Zhikang Yu; Zhixiong Zhong
Journal:  J Clin Lab Anal       Date:  2021-10-06       Impact factor: 2.352

Review 4.  Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.

Authors:  Yitian Zhou; Volker M Lauschke
Journal:  Hum Genet       Date:  2021-10-15       Impact factor: 5.881

5.  Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.

Authors:  Barbara A Jennings; Yoon K Loke; Jane Skinner; Melanie Keane; Gavin S Chu; Richard Turner; Daniel Epurescu; Ann Barrett; Gavin Willis
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.